As such, FoxO3a is considered a potential therapeutic target for the treatment of AD and may even act directly with PGC-1α gene, a key positive regulator of oxidative metabolism, exhibits a noteworthy reduction in AD patients’ brains, consequently decreasing OS [89,90]. The gene discussed is PPARGC1A; the disease is Alzheimer disease.